Duloxetine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Anxiety Disorder

• Alprazolam
• Buspirone
• Escitalopram
• Lorazepam
• Paroxetine
• Sertraline
• Venlafaxine

Also listed for Chronic Pain

• Gabapentin

Other medications in Mental Health

• Esketamine Nasal
• Fluoxetine
• Fluphenazine
• Fluvoxamine
• Guanfacine
• Haloperidol
• Iloperidone
• Imipramine

What Duloxetine is approved for (FDA label)

Duloxetine delayed-release capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatric patients 13 years of age and older Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older ( 1 ) Chronic musculoskeletal pain in adults ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Duloxetine (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions ( 5.1 )] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions ( 5.1 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Duloxetine (FDA label)

Duloxetine delayed-release capsules are available as: 20 mg white and blue capsules imprinted with “ap DLX20” 30 mg blue and blue capsules imprinted with “ap DLX30” 40 mg pink and blue capsules imprinted with “ap DLX40” 60 mg white and blue capsules imprinted with “ap DLX60” Delayed-release capsules 20 mg, 30 mg, 40 mg and 60 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Duloxetine (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults [see Boxed Warning and Warnings and Precautions ( 5.1 )] Hepatotoxicity [see Warnings and Precautions ( 5.2 )] Orthostatic Hypotension, Falls and Syncope [see Warnings and Precautions ( 5.3 )] Serotonin Syndrome [see Warnings and Precautions ( 5.4 )] Increased Risk of Bleeding [see Warnings and Precautions ( 5.5 )] Severe Skin Reactions [see Warnings and Precautions ( 5.6 )] Discontinuation Syndrome [see Warnings and Precautions ( 5.7 )] Activation of Mania/Hypomania [see Warnings and Precautions ( 5.8 )] Angle-Closure Glaucoma [see Warnings and Precautions ( 5.9 )] Seizures [see Warnings and Precautions ( 5.10 )] Increases in Blood Pressure [see Warnings and Precautions ( 5.11 )] Clinically Important Drug Interactions [see Warnings and Precautions ( 5.12 )] Hyponatremia [see Warnings and Precautions ( 5.13 )] Urinary Hesitation and Retention [see Warnings and Precautions ( 5.15 )] Sexual Dysfunction [see Warnings and Precautions ( 5.16 )] Most common adverse reactions (greater than or equal to 5% and at least twice the incidence of placebo-treated patients): ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Duloxetine (FDA label)

The use of MAOIs intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is contraindicated [see Dosage and Administration ( 2.8 ) and Warnings and Precautions ( 5.4 )]. Starting duloxetine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.9 ) and Warnings and Precautions ( 5.4 )]. Concomitant use of an MAOI antidepressant with duloxetine is contraindicated Use of duloxetine within 14 days of stopping an MAOI antidepressant is contraindicated In linezolid-or intravenous methylene blue-treated patients, initiation of duloxetine is contraindicated ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Duloxetine (FDA label)

Hepatotoxicity : Hepatic failure, sometimes fatal, has been reported. Discontinue duloxetine in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Avoid use in patients with substantial alcohol use or evidence of chronic liver disease ( 5.2 ) Orthostatic Hypotension, Falls and Syncope : Consider dosage reduction or discontinuation if these events occur ( 5.3 ) Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. If it occurs, discontinue duloxetine and serotonergic agents ( 5.4 ) Increased Risk of Bleeding : May increase the risk of bleeding events.

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Duloxetine (FDA label)

Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism. Potent inhibitors of CYP1A2 should be avoided ( 7.1 ). Potent inhibitors of CYP2D6 may increase duloxetine concentrations ( 7.2 ). Duloxetine is a moderate inhibitor of CYP2D6 ( 7.9 ). 7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C max was increased about 2.5-fold, and duloxetine t 1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see Warnings and Precautions ( 5.12 )] . 7.2 Inhibitors of CYP2D6 Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.

Source: FDA prescribing information (DailyMed). Set ID: 79bfd6be-a1ff-4786-b4e2-abbd0a3e3932. SPL document ID: 5b063723-7f0a-3541-e063-6294a90ad207. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.